Histiocytic Disorders

Types of Histiocytic Disorders

• Langerhans Cell Histiocytosis (LCH):
  A rare disorder characterised by the proliferation of Langerhans cells, a type of dendritic cell normally found in the skin, lungs, and other tissues. In LCH, these cells become abnormal and form lesions that can infiltrate organs such as the skin, bones, lungs, liver, spleen, and lymph nodes.
  
  Symptoms of LCH include:
  • Skin rashes
  • Bone pain or fractures due to bone lesions
  • Swollen lymph nodes (lymphadenopathy)
  • Cough or shortness of breath
  • Enlarged liver and spleen (hepatosplenomegaly)
  • Diabetes insipidus from pituitary involvement
  LCH can affect both children and adults. In children it may be aggressive, while in adults it often follows a slower course.
• Non-Langerhans Cell Histiocytosis:
  A group of disorders involving abnormal proliferation or activation of macrophages. These conditions vary widely in severity and are less well understood than LCH.

Systemic Histiocytic Disorders

• Hemophagocytic Lymphohistiocytosis (HLH):
  A life-threatening condition caused by excessive activation of histiocytes and lymphocytes, leading to uncontrolled inflammation and organ damage. HLH may be triggered by infections, malignancies, autoimmune diseases, or inherited genetic mutations.
  
  Symptoms of HLH include:
  • Persistent fever
  • Enlarged liver and spleen
  • Cytopenias (low blood cell counts)
  • High ferritin levels (hyperferritinemia)
  • Skin rash
  • Organ failure, especially liver and bone marrow failure
• Macrophage Activation Syndrome (MAS):
  A secondary form of HLH occurring in autoimmune conditions such as systemic juvenile idiopathic arthritis and systemic lupus erythematosus. It presents with fever, organ dysfunction, and elevated inflammatory markers like ferritin.
• Rosai–Dorfman Disease:
  A rare, usually benign disorder involving non-Langerhans histiocytes infiltrating lymph nodes and other organs. Symptoms include lymphadenopathy, fever, weight loss, and sometimes skin, bone, or organ involvement. It is often self-limiting but may require treatment in severe cases.
• Erdheim–Chester Disease:
  A rare non-Langerhans histiocytosis characterised by histiocyte infiltration of bones and multiple organs such as the heart, lungs, kidneys, and retroperitoneum. It is associated with BRAF gene mutations and often presents with bilateral long-bone sclerosis and organ involvement.
• Familial Histiocytic Disorders:
  Inherited conditions such as familial hemophagocytic lymphohistiocytosis (FHL), caused by mutations in immune-regulating genes leading to hyperactivation of histiocytes.

Common Symptoms

• Fever
• Enlarged lymph nodes
• Bone pain or bone lesions
• Skin rashes or lesions
• Enlarged liver and spleen
• Neurological symptoms (headaches, seizures, nerve damage)
• Breathing difficulties
• Fatigue and weight loss
• Jaundice

Diagnosis

• Clinical evaluation: Assessment of symptoms and physical findings
• Blood tests: CBC, liver and kidney tests, ferritin levels
• Imaging: X-ray, CT, or MRI to detect organ or bone involvement
• Biopsy: Tissue sampling with immunohistochemistry to identify histiocytes
• Genetic testing: Detection of mutations such as BRAF or familial HLH genes
• Bone marrow biopsy: If marrow involvement is suspected

Treatment

• Chemotherapy: For aggressive disorders such as LCH or HLH
• Steroids: To suppress inflammation and immune activation
• Immunotherapy: Monoclonal antibodies (e.g., rituximab, infliximab)
• Targeted therapy: BRAF inhibitors such as vemurafenib
• Stem cell transplantation: For severe or familial HLH
• Supportive care: Infection prevention, transfusions, and symptom control

Prognosis

• Depends on disease type, organ involvement, and speed of diagnosis
• Conditions like Rosai–Dorfman disease may have good outcomes
• HLH can be life-threatening without prompt treatment
• Early diagnosis significantly improves outcomes